KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Goodwill (2017 - 2025)

Amneal Pharmaceuticals has reported Goodwill over the past 9 years, most recently at $595.5 million for Q4 2025.

  • Quarterly results put Goodwill at $595.5 million for Q4 2025, changed 0.33% from a year ago — trailing twelve months through Dec 2025 was $595.5 million (changed 0.33% YoY), and the annual figure for FY2025 was $595.5 million, changed 0.33%.
  • Goodwill for Q4 2025 was $595.5 million at Amneal Pharmaceuticals, roughly flat from $595.9 million in the prior quarter.
  • Over the last five years, Goodwill for AMRX hit a ceiling of $602.9 million in Q1 2022 and a floor of $522.8 million in Q1 2021.
  • Median Goodwill over the past 5 years was $598.4 million (2024), compared with a mean of $590.4 million.
  • Biggest five-year swings in Goodwill: increased 15.33% in 2022 and later fell 0.62% in 2023.
  • Amneal Pharmaceuticals' Goodwill stood at $593.0 million in 2021, then grew by 0.98% to $598.9 million in 2022, then dropped by 0.04% to $598.6 million in 2023, then fell by 0.2% to $597.4 million in 2024, then decreased by 0.33% to $595.5 million in 2025.
  • The last three reported values for Goodwill were $595.5 million (Q4 2025), $595.9 million (Q3 2025), and $597.4 million (Q2 2025) per Business Quant data.